Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

Rhea-AI Summary

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company, has announced it will report its third quarter 2024 financial results after market close on October 31, 2024. Following this, the company will host a conference call and webcast at 4:30 pm Eastern Time on the same day to discuss the financial results and provide a corporate update.

Zymeworks develops a diverse pipeline of novel, multifunctional biotherapeutics aimed at improving the standard of care for difficult-to-treat diseases. The event will be webcast live, and both dial-in details and webcast replays will be available on the company's investor relations website at https://ir.zymeworks.com/events-and-presentations.

VANCOUVER, British Columbia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that management will report its third quarter 2024 financial results after market close on October 31, 2024. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on October 31, 2024 at 4:30 pm Eastern Time (ET).

The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations

About Zymeworks Inc.

Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat cancers and other diseases. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers. A Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) has been accepted and granted Priority Review. A BLA has also been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. If approved, zanidatamab would be the first HER2-targeted treatment specifically approved for BTC in the U.S. and China.
Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting at sites worldwide. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Contacts:

Investor Inquiries:
Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
ir@zymeworks.com   

Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com

FAQ

When will Zymeworks (ZYME) report its Q3 2024 financial results?

Zymeworks (ZYME) will report its third quarter 2024 financial results after market close on October 31, 2024.

What time is Zymeworks' (ZYME) Q3 2024 earnings call scheduled for?

Zymeworks' (ZYME) Q3 2024 earnings call is scheduled for October 31, 2024 at 4:30 pm Eastern Time.

Where can I find the webcast details for Zymeworks' (ZYME) Q3 2024 earnings call?

The webcast details and replay for Zymeworks' (ZYME) Q3 2024 earnings call will be available on the company's website at https://ir.zymeworks.com/events-and-presentations.

What does Zymeworks (ZYME) specialize in as a biotechnology company?

Zymeworks (ZYME) is a clinical-stage biotechnology company that develops a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases.